Patients in the US with serious lung disease idiopathic pulmonary fibrosis (IPF) have gone from no approved drugs to two after the FDA cleared products from Roche and Boehringer Ingelheim. The ...
Also listed among discontinued trials in Roche's update is its Alzheimer's drug gantenerumab – as previously announced – along with a phase 3 study of idiopathic pulmonary fibrosis (IPF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback